Contents lists available at ScienceDirect
IJC Heart & Vasculature j o u r n a l h o m e p a g e : h t t p : / / w w w . j o u r n a l s . e l s e v i e r . c o m / i j c -h e a r t -a n d -v a s c u l a t u r e 1 (MTF-1; TGCRCNC) and hypoxia inducible factors (HIFs; RCGTG). These transcription factors and c-Myc (CACGTG) might bind and cofunction on CGCGTGCGCACGTG sequences, which are termed NMHs. SLC5A7 (a choline transporter) is known to be associated with heart rate variability. SLC5A7 has an NMH that is 481 Kb from the ATG start codon that contains the sequence TGTGTGTGTGTGTGT GTGTGCGCGC ACACG (termed FRONT1) before the NMH. A 29-nt FRONT1 is included in the ncRNA (LOC 101927056), and a 30-nt FRONT1 is included in the near regions of genes such as FZD7 (cardiac differentiation), SERPINE2, FAM124B, OR2A2, LAMP3, CSMD1, SOX-11 and GRM1. Additionally, FRONT1 is highly conserved in Sjogren syndrome antigen B (SSB), which is associated with cardiovascular disease, PDIA6, PPARA (acute myocardial infarction), PDE3A (cardiac remodeling), CRIM1 (chronic heart failure), AFF2, SOX2-OT and PAX4 (transcriptional modulator) (Fig. 1) . Some of these genes are associated with cardiovascular disease.
Initially, FRONT1 + NMH might be activated, and ncRNA might subsequently be activated by FRONT1. The FRONT1 of LOC 101927056 has no NMH at all. Finally, ncRNA might activate many other genes, and these genes might form a network that changes the characteristics of to survive under new hypoxic and undernourished conditions. Cardiovascular agents cannot reach the pathologic parts of the heart through occluded microvessels. I have reported some PVT cases in which warfarin [1] and dabigatran [3] [4] [5] 10] dissolved the PVTs. Warfarin and dabigatran might ameliorate cardiovascular disease by increasing microarterial blood flow. FRONT1 might be useful as a novel prognostic factor and a new target for the development of drugs for cardiovascular disease. Microclots released from PVTs might occlude small coronary arteries and cause slow flow syndrome of the coronary arteries. To clarify these relationships, additional studies are needed. It is important to use 64-MDCT to demonstrate PVTs when we estimate the effects of anticoagulants on PVTs.
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